ReviewFrontiers in immunology2020
Interleukin-1 as Innate Mediator of T Cell Immunity.
Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 119 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
119 citing papers in PubMed, 198 citations in OpenAlex.
- Effects of Sirolimus treatment on patients with β-Thalassemia: Lymphocyte immunophenotype and biological activity of memory CD4Journal of cellular and molecular medicine · 2023Trial
- Topical framework nucleic acid transdermal delivery system for reprogramming cutaneous dendritic cells to maintain graft immune homeostasis.Bioactive materials · 2026Article
- Early-Life Exposures and Risk of Multiple Myeloma: A Population-Based Case-Control Study in Australia.International journal of cancer · 2026Article
- Study on the Therapeutic Effects of Ginsenoside Rh2 in Asthma Improvement.International journal of molecular sciences · 2026Article
- Immune system evaluation of Echinacea Purpurea root extract in female Harlan Sprague Dawley (Hsd:Sprague Dawley SD) rats.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2026Article
- Tissue-Resident Macrophage in Inflammation and Cancer.MedComm · 2026Review
- Profiling the T cell response to polypropylene mesh in a non-human primate sacrocolpopexy model.Biomaterials · 2026Article
- The dual balance of the cytokine network: key messengers of immune activation and triggers of cytokine storm.Biomarker research · 2026Review
- The Memory Inflation Response Against Spread-Defective CMV Requires Priming-Independent CD4European journal of immunology · 2026Article
- Immunogenic Cell Death: Unlocking New Frontiers in Cancer Immunotherapy.Cancer innovation · 2026Review
- Monocyte-derived IL-1β predicts and promotes HBsAg decline in chronic hepatitis B patients under nucleoside analogue therapy.Hepatology communications · 2026Article
- Discovery of 7-azaindole-3-acrylamide inhibitors of inflammasomes/IL-1β for the treatment of inflammatory bowel disease.Molecular diversity · 2026Article
- Article
- An autologous cell-based therapeutic vaccine expressing IL6/1 fusokine drives robust anti-tumor response against ovarian cancer.bioRxiv : the preprint server for biology · 2026Article
- Immune microenvironment in autosomal dominant polycystic kidney disease.Genes & diseases · 2026Review
- Early cytokine and chemokine signals shape the anti-AML activity of bispecific engager-secreting T cells.Haematologica · 2026Article
- Host Responses to SARS-CoV-2 with an Emphasis on Cytokines.International journal of molecular sciences · 2026Review
- Immunopathogenesis and immunoregulatory mechanisms in allergic contact dermatitis.Frontiers in immunology · 2026Review
- Targeting IL-1β: a potential strategy for alleviating the immunopathology of aortic aneurysms.Frontiers in immunology · 2026Review
- Overcoming impaired antigen presentation in tumor-draining lymph nodes facilitates immunotherapy.Journal for immunotherapy of cancer · 2025Article
59 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The three-signal paradigm tries to capture how the innate immune system instructs adaptive immune responses in three well-defined actions: (1) presentation of antigenic peptides in the context of MHC molecules, which allows for a specific T cell response; (2) T cell co-stimulation, which breaks T cell tolerance; and (3) secretion of polarizing cytokines in the priming environment, thereby specializing T cell immunity. The three-signal model provides an empirical framework for innate instruction of adaptive immunity, but mainly discusses STAT-dependent cytokines in T cell activation and differentiation, while the multi-faceted roles of type I IFNs and IL-1 cytokine superfamily members are often neglected. IL-1α and IL-1β are pro-inflammatory cytokines, produced following damage to the host (release of DAMPs) or upon innate recognition of PAMPs. IL-1 activity on both DCs and T cells can further shape the adaptive immune response with variable outcomes. IL-1 signaling in DCs promotes their ability to induce T cell activation, but also direct action of IL-1 on both CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.